Single Administration of GenVec's Vaccine Provides Protective Immunity Against HSV in Pre-clinical Animal Models

Single Administration of GenVec's Vaccine Provides Protective Immunity Against
                      HSV in Pre-clinical Animal Models

PR Newswire

GAITHERSBURG, Md., Dec. 17, 2012

GAITHERSBURG, Md., Dec. 17, 2012 /PRNewswire/ --GenVec, Inc. (NASDAQ:GNVC)
announced today that data were presented on its HSV vaccine program at the
Keystone Symposia meeting on Immunological Mechanisms of Vaccination, which is
taking place in Ottawa, Ontario from December 13 to December 18, 2012.

The company disclosedthat a single administration ofits genetic vaccine was
effective against HSV2 in two industry-accepted HSV disease models.
Specifically, immunization was shown to reduce viral shedding, and the
recurrence and severity of lesions.

GenVec's HSV vaccine candidate generated effective immune responses in animal
models; and is composed of two novel antigens, as well as a proprietary,
non-human adenoviral vector.

"We have substantial evidence that HSV infection can be controlled by inducing
an appropriate T-cell response," said Dr. Lisa Wei, Senior Director of
Research and head of GenVec's HSV program. "The data presented at this
symposium demonstrate the progress we are making towards the goal of creating
a vaccine for treatment and potentially prophylaxis of HSV infection."

Research reported in this release was supported by the National Institute of
Allergy and Infectious Diseases of the National Institutes of Health under
grant number 5R43AIO77147-02. The content is solely the responsibility of the
authors and does not necessarily represent the official views of the National
Institutes of Health.

About Herpes Simplex Virus (HSV)

In the United States, approximately 40 million people are currently infected
with HSV2, which is responsible for most cases of genital herpes, and 1.6
million new infections occur each year. About 25% of those infected with the
virus suffer clinical symptoms. Even higher infection rates are evident in
developing countries.HSV2 infection is associated with increased HIV
infection and transmission; and further complications of HSV are also often
seen in those co-infected with HIV. HSV infections are permanent, and result
in periodic virus shedding.Although antiviral regimens have become a standard
of care, their inconvenience, cumulative cost and potential for drug
resistance further underscore the need for safe, new approaches to reduce HSV
lesions, virus shedding, and transmission. Estimated costs of treating HSV in
the United States alone are close to $1 billion, primarily for drugs and
outpatient medical care. There is no FDA-approved vaccine for HSV.

About GenVec

GenVec is a biopharmaceutical company using differentiated, proprietary
technologies to create superior therapeutics and vaccines. A key component of
our strategy is to develop and commercialize our product candidates through
collaborations. GenVec is working with leading companies and organizations
such as Novartis, Merial, and the U.S. Government to support a portfolio of
product programs that address the prevention and treatment of a number of
significant human and animal health concerns. GenVec's development programs
address therapeutic areas such as hearing loss and balance disorders; as well
as vaccines against infectious diseases including respiratory syncytial virus
(RSV), herpes simplex virus (HSV), dengue fever, malaria, and human
immunodeficiency virus (HIV). In the area of animal health we are developing
vaccines against foot-and-mouth disease (FMD). Additional information about
GenVec is available at www.genvec.com and in the Company's filings with the
U.S. Securities and Exchange Commission.

Statements herein relating to future financial or business performance,
conditions or strategies and other financial and business matters, including
expectations regarding funding, grants, collaborations, revenues, cash burn
rates, the development of products and the success of the Company's
collaborations, including with Novartis and Merial, are forward-looking
statements within the meaning of the Private Securities Litigation Reform
Act. GenVec cautions that these forward-looking statements are subject to
numerous assumptions, risks and uncertainties, which change over time. Factors
that may cause actual results to differ materially from the results discussed
in the forward-looking statements or historical experience include risks and
uncertainties, including the failure by GenVec to secure and maintain
relationships with collaborators; risks relating to the early stage of
GenVec's product candidates under development; uncertainties relating to
research and development activities; risks relating to the commercialization,
if any, of GenVec's proposed product candidates; dependence on the efforts of
collaborators and third parties; dependence on intellectual property;
currently unanticipated expenses, and risks that we may lack the financial
resources and access to capital to fund our operations. Further information
on the factors and risks that could affect GenVec's business, financial
conditions and results of operations, are contained in GenVec's filings with
the U.S. Securities and Exchange Commission (SEC), which are available at
www.sec.gov. These forward-looking statements speak only as of the date of
this press release, and GenVec assumes no duty to update forward-looking
statements.

Retail Investor and Media Contact Institutional Investor Contact
GenVec, Inc.                      S.A. Noonan Communications
Douglas J. Swirsky                Susan A. Noonan
(240) 632-5510                    (212) 966-3650
dswirsky@genvec.com               susan@sanoonan.com

SOURCE GenVec, Inc.

Website: http://www.genvec.com